Switch to:
Also traded in: Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.07
NYSE:FMS's Cash to Debt is ranked lower than
77% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. NYSE:FMS: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:FMS' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.06 Max: N/A
Current: 0.07
Equity to Asset 0.40
NYSE:FMS's Equity to Asset is ranked lower than
62% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. NYSE:FMS: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:FMS' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.4 Max: 0.5
Current: 0.4
0.34
0.5
Interest Coverage 5.33
NYSE:FMS's Interest Coverage is ranked lower than
61% of the 213 Companies
in the Global Medical Care industry.

( Industry Median: 7.76 vs. NYSE:FMS: 5.33 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:FMS' s Interest Coverage Range Over the Past 10 Years
Min: 3.55  Med: 4.68 Max: 6.3
Current: 5.33
3.55
6.3
F-Score: 5
Z-Score: 2.45
M-Score: -2.52
WACC vs ROIC
4.10%
9.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.31
NYSE:FMS's Operating margin (%) is ranked higher than
74% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 6.84 vs. NYSE:FMS: 14.31 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:FMS' s Operating margin (%) Range Over the Past 10 Years
Min: 13.9  Med: 15.69 Max: 16.51
Current: 14.31
13.9
16.51
Net-margin (%) 6.67
NYSE:FMS's Net-margin (%) is ranked higher than
61% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. NYSE:FMS: 6.67 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:FMS' s Net-margin (%) Range Over the Past 10 Years
Min: 6.15  Med: 7.65 Max: 8.6
Current: 6.67
6.15
8.6
ROE (%) 11.63
NYSE:FMS's ROE (%) is ranked higher than
59% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 9.67 vs. NYSE:FMS: 11.63 )
Ranked among companies with meaningful ROE (%) only.
NYSE:FMS' s ROE (%) Range Over the Past 10 Years
Min: 11.29  Med: 13.36 Max: 14.68
Current: 11.63
11.29
14.68
ROA (%) 4.51
NYSE:FMS's ROA (%) is ranked higher than
53% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. NYSE:FMS: 4.51 )
Ranked among companies with meaningful ROA (%) only.
NYSE:FMS' s ROA (%) Range Over the Past 10 Years
Min: 4.29  Med: 5.3 Max: 6.22
Current: 4.51
4.29
6.22
ROC (Joel Greenblatt) (%) 39.44
NYSE:FMS's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 18.74 vs. NYSE:FMS: 39.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:FMS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 38.32  Med: 44.23 Max: 50.61
Current: 39.44
38.32
50.61
Revenue Growth (3Y)(%) 13.70
NYSE:FMS's Revenue Growth (3Y)(%) is ranked higher than
72% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. NYSE:FMS: 13.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:FMS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.6  Med: 6.1 Max: 13.7
Current: 13.7
-4.6
13.7
EBITDA Growth (3Y)(%) 8.40
NYSE:FMS's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 7.40 vs. NYSE:FMS: 8.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:FMS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 7.6 Max: 43.2
Current: 8.4
0
43.2
EPS Growth (3Y)(%) 1.70
NYSE:FMS's EPS Growth (3Y)(%) is ranked lower than
65% of the 133 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. NYSE:FMS: 1.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:FMS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: 12.9 Max: 62.7
Current: 1.7
-17.6
62.7
» NYSE:FMS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

FMS Guru Trades in Q4 2015

Jim Simons 39,150 sh (New)
Keeley Asset Management Corp 40,000 sh (unchged)
Manning & Napier Advisors, Inc 312,560 sh (unchged)
» More
Q1 2016

FMS Guru Trades in Q1 2016

Manning & Napier Advisors, Inc 312,560 sh (unchged)
Jim Simons Sold Out
Keeley Asset Management Corp Sold Out
» More
Q2 2016

FMS Guru Trades in Q2 2016

Jim Simons 91,400 sh (New)
Manning & Napier Advisors, Inc 310,060 sh (-0.80%)
» More
Q3 2016

FMS Guru Trades in Q3 2016

Manning & Napier Advisors, Inc 338,470 sh (+9.16%)
Jim Simons 59,300 sh (-35.12%)
» More
» Details

Insider Trades

Latest Guru Trades with FMS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Fresenius Medical Care AG & Co. KGaA

SymbolPriceYieldDescription
FME3.Germany54.200.96

Business Description

Industry: Health Care Providers » Medical Care
Compare:NYSE:HCA, NYSE:DVA, NYSE:UHS, OTCPK:RMSYF, OTCPK:FSNUY, OTCPK:SKHCY, NYSE:MD, NAS:WOOF, NYSE:HLS, NAS:AMSG, NAS:ACHC, NYSE:CHE, OTCPK:LTGHY, NAS:LPNT, NAS:SCAI, NYSE:SEM, NYSE:THC, NYSE:AMN, NAS:AMED, NAS:PAHC » details
Traded in other countries:FMEN.Germany, FME.Italy, FME N.Mexico, FME.Switzerland, 0H9X.UK, FMCQF.USA,
Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company, which is operating in both the field of dialysis products and dialysis services.

Fresenius Medical Care AG & Co. KGaA was incorporated on August 5, 1996. It is a kidney dialysis company, operating in both the field of dialysis products and the field of dialysis services. The Company's dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with different products. In addition, to providing dialysis treatments, includes pharmacy services and vascular access surgery services. It sells dialysis products to other dialysis service providers. It also develops and manufactures equipment, systems and disposable products, which it sells to customers in over 120 countries. It offers life-maintaining and life-saving dialysis services and products in a market which is characterized by a favorable demographic development. It provides expanded and enhanced patient services, including renal pharmaceutical products and laboratory services, to both its own clinics and those of third parties. The Company's clinics also provide services for home dialysis patients, the majority of whom receive peritoneal dialysis treatment. It also provides dialysis services under contract to hospitals in the U.S. on an 'as needed' basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. The Company provides laboratory testing and marketing services in the U.S. through Spectra Laboratories (Spectra). Spectra provides blood, urine and other bodily fluid testing services to determine the appropriate individual dialysis therapy for a patient and to assist physicians in determining whether a dialysis patient's therapy regimen, diet and medicines remain optimal. The Company operates in geographical segments including the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment. The Company's main trademarks are the name 'Fresenius' and the 'F' logo'. The Company's competitors in the sale of hemodialysis and peritoneal dialysis products include, Baxter International Inc., Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc. The Company's operations are subject to extensive governmental regulation by virtually every country in which it operates, including the U.S., at the federal, state and local levels.

Ratios

vs
industry
vs
history
P/E(ttm) 20.96
FMS's P/E(ttm) is ranked higher than
63% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 25.07 vs. FMS: 20.96 )
Ranked among companies with meaningful P/E(ttm) only.
FMS' s P/E(ttm) Range Over the Past 10 Years
Min: 13.33  Med: 20.03 Max: 29.4
Current: 20.96
13.33
29.4
Forward P/E 16.21
FMS's Forward P/E is ranked lower than
51% of the 53 Companies
in the Global Medical Care industry.

( Industry Median: 16.18 vs. FMS: 16.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.96
FMS's PE(NRI) is ranked higher than
64% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 25.14 vs. FMS: 20.96 )
Ranked among companies with meaningful PE(NRI) only.
FMS' s PE(NRI) Range Over the Past 10 Years
Min: 13.35  Med: 20.02 Max: 29.4
Current: 20.96
13.35
29.4
Price/Owner Earnings (ttm) 26.59
FMS's Price/Owner Earnings (ttm) is ranked lower than
51% of the 88 Companies
in the Global Medical Care industry.

( Industry Median: 25.79 vs. FMS: 26.59 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
FMS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.38  Med: 21.79 Max: 36.52
Current: 26.59
12.38
36.52
P/B 2.35
FMS's P/B is ranked higher than
52% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 2.39 vs. FMS: 2.35 )
Ranked among companies with meaningful P/B only.
FMS' s P/B Range Over the Past 10 Years
Min: 1.64  Med: 2.53 Max: 3.01
Current: 2.35
1.64
3.01
P/S 1.40
FMS's P/S is ranked higher than
52% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.45 vs. FMS: 1.40 )
Ranked among companies with meaningful P/S only.
FMS' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 1.51 Max: 1.89
Current: 1.4
1.02
1.89
PFCF 31.09
FMS's PFCF is ranked lower than
66% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. FMS: 31.09 )
Ranked among companies with meaningful PFCF only.
FMS' s PFCF Range Over the Past 10 Years
Min: 14.05  Med: 24.86 Max: 53.67
Current: 31.09
14.05
53.67
POCF 13.32
FMS's POCF is ranked higher than
57% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 14.12 vs. FMS: 13.32 )
Ranked among companies with meaningful POCF only.
FMS' s POCF Range Over the Past 10 Years
Min: 9.4  Med: 12.68 Max: 19.32
Current: 13.32
9.4
19.32
EV-to-EBIT 12.94
FMS's EV-to-EBIT is ranked higher than
75% of the 190 Companies
in the Global Medical Care industry.

( Industry Median: 19.66 vs. FMS: 12.94 )
Ranked among companies with meaningful EV-to-EBIT only.
FMS' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.3  Med: 12.5 Max: 16.8
Current: 12.94
7.3
16.8
EV-to-EBITDA 10.03
FMS's EV-to-EBITDA is ranked higher than
74% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. FMS: 10.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
FMS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.8  Med: 10 Max: 13
Current: 10.03
5.8
13
PEG 2.58
FMS's PEG is ranked higher than
52% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 2.64 vs. FMS: 2.58 )
Ranked among companies with meaningful PEG only.
FMS' s PEG Range Over the Past 10 Years
Min: 1.03  Med: 2.15 Max: 12.63
Current: 2.58
1.03
12.63
Shiller P/E 27.06
FMS's Shiller P/E is ranked higher than
51% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 27.06 vs. FMS: 27.06 )
Ranked among companies with meaningful Shiller P/E only.
FMS' s Shiller P/E Range Over the Past 10 Years
Min: 20.67  Med: 28.56 Max: 44.54
Current: 27.06
20.67
44.54
Current Ratio 1.37
FMS's Current Ratio is ranked higher than
54% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. FMS: 1.37 )
Ranked among companies with meaningful Current Ratio only.
FMS' s Current Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.41 Max: 1.93
Current: 1.37
0.8
1.93
Quick Ratio 1.11
FMS's Quick Ratio is ranked lower than
52% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. FMS: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
FMS' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.15 Max: 1.61
Current: 1.11
0.7
1.61
Days Inventory 41.82
FMS's Days Inventory is ranked lower than
72% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 18.12 vs. FMS: 41.82 )
Ranked among companies with meaningful Days Inventory only.
FMS' s Days Inventory Range Over the Past 10 Years
Min: 32.59  Med: 36.33 Max: 41.82
Current: 41.82
32.59
41.82
Days Sales Outstanding 74.53
FMS's Days Sales Outstanding is ranked lower than
82% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. FMS: 74.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
FMS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.64  Med: 77.71 Max: 85.55
Current: 74.53
71.64
85.55
Days Payable 16.01
FMS's Days Payable is ranked lower than
79% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 38.65 vs. FMS: 16.01 )
Ranked among companies with meaningful Days Payable only.
FMS' s Days Payable Range Over the Past 10 Years
Min: 16.01  Med: 19.69 Max: 35.89
Current: 16.01
16.01
35.89

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.17
FMS's Dividend Yield is ranked lower than
62% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 1.60 vs. FMS: 1.17 )
Ranked among companies with meaningful Dividend Yield only.
FMS' s Dividend Yield Range Over the Past 10 Years
Min: 0.93  Med: 1.33 Max: 2.07
Current: 1.17
0.93
2.07
Dividend Payout 0.24
FMS's Dividend Payout is ranked higher than
72% of the 137 Companies
in the Global Medical Care industry.

( Industry Median: 0.38 vs. FMS: 0.24 )
Ranked among companies with meaningful Dividend Payout only.
FMS' s Dividend Payout Range Over the Past 10 Years
Min: 0.24  Med: 1.08 Max: 1.36
Current: 0.24
0.24
1.36
Dividend Growth (3y) 6.40
FMS's Dividend Growth (3y) is ranked lower than
68% of the 71 Companies
in the Global Medical Care industry.

( Industry Median: 17.10 vs. FMS: 6.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
FMS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8
Current: 6.4
0
8
Forward Dividend Yield 1.18
FMS's Forward Dividend Yield is ranked lower than
62% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 1.66 vs. FMS: 1.18 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.62
FMS's Yield on cost (5-Year) is ranked lower than
61% of the 307 Companies
in the Global Medical Care industry.

( Industry Median: 2.27 vs. FMS: 1.62 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
FMS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.29  Med: 1.84 Max: 2.86
Current: 1.62
1.29
2.86
3-Year Average Share Buyback Ratio 0.20
FMS's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. FMS: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FMS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.3  Med: -0.8 Max: 10.9
Current: 0.2
-12.3
10.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.18
FMS's Price/Projected FCF is ranked higher than
69% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 1.64 vs. FMS: 1.18 )
Ranked among companies with meaningful Price/Projected FCF only.
FMS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.31 Max: 2
Current: 1.18
0.78
2
Price/DCF (Earnings Based) 1.51
FMS's Price/DCF (Earnings Based) is ranked higher than
58% of the 31 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. FMS: 1.51 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.93
FMS's Price/Median PS Value is ranked higher than
62% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 1.00 vs. FMS: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
FMS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 0.97 Max: 1.63
Current: 0.93
0.2
1.63
Price/Peter Lynch Fair Value 2.60
FMS's Price/Peter Lynch Fair Value is ranked lower than
52% of the 42 Companies
in the Global Medical Care industry.

( Industry Median: 2.54 vs. FMS: 2.60 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
FMS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.94  Med: 2.08 Max: 4.26
Current: 2.6
0.94
4.26
Earnings Yield (Greenblatt) (%) 7.70
FMS's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. FMS: 7.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FMS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.9  Med: 8 Max: 13.7
Current: 7.7
5.9
13.7
Forward Rate of Return (Yacktman) (%) 11.99
FMS's Forward Rate of Return (Yacktman) (%) is ranked higher than
55% of the 113 Companies
in the Global Medical Care industry.

( Industry Median: 10.28 vs. FMS: 11.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
FMS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5  Med: 11.3 Max: 16.5
Current: 11.99
-5
16.5

More Statistics

Revenue (TTM) (Mil) $17,572
EPS (TTM) $ 1.92
Beta0.80
Short Percentage of Float0.24%
52-Week Range $38.05 - 47.52
Shares Outstanding (Mil)612.28

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 18,080 19,505 20,977
EPS ($) 2.90 3.37 3.75
EPS w/o NRI ($) 2.90 3.37 3.75
EPS Growth Rate
(3Y to 5Y Estimate)
11.89%
Dividends Per Share ($) 0.52 0.55 0.51
» More Articles for NYSE:FMS

Headlines

Articles On GuruFocus.com
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
Weekly 52-Week Highs Highlight: FMS, MTB, LO, LEN Apr 05 2015 
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 
Weekly 52-Week Highs Highlight: MMP, AZO, BEAM, FMS Jan 26 2014 
Better Know a Company: Fresenius Medical Care (FMS) Apr 23 2013 
Warren Buffett Becomes Largest Owner of DaVita Mar 04 2013 
Warren Buffett’s Holding of DaVita Grows as Company Expands Jan 17 2013 
Buffett’s Berkshire Hathaway Buys Even More DaVita Shares Nov 29 2012 
Edward Owens Buys Walgreen Co., UCBH Holdings Inc., OSI Pharmaceuticals Inc., Sells Ventana Medical Aug 02 2007 
Kenneth Fisher: Surviving Rate Rises Jun 04 2006 

More From Other Websites
Fresenius Medical Care will focus on IFRS reporting and discontinue U.S. GAAP financial statements Dec 01 2016
Is Humana Inc (HUM) A Good Stock To Buy Right Now? Dec 01 2016
Leading Investors Aren’t Sure What to Make of Dollar General Corp. (DG) Nov 24 2016
Influenza Vaccination Keeps Dialysis Patients Out of the Hospital Nov 18 2016
Fresenius Medical Care Showcases Breadth and Depth of Clinical Research with Nearly 70 Abstracts... Nov 17 2016
Capital Square 1031 Acquires Medical Building in Eastern North Carolina Nov 09 2016
European Stock Markets Rally After Early Morning Bloodbath, Trump Concerns Ease Nov 09 2016
ETF’s with exposure to Fresenius Medical Care AG & Co. KGaA : November 2, 2016 Nov 02 2016
Fresenius Medical (FMS) Q3 Earnings, Sales Beat Estimates Nov 02 2016
The Healthcare Facility Space Just Got A Little Smaller Oct 31 2016
Fresenius Medical Care AG & Co. KGaA :FMS-US: Earnings Analysis: Q3, 2016 By the Numbers : October... Oct 31 2016
Fresenius beats Street 3Q forecasts Oct 27 2016
Fresenius beats Street 3Q forecasts Oct 27 2016
Obamacare is less of an issue for Fresenius: CEO Oct 27 2016
Fresenius Medical Care reports strong third quarter and confirms full year guidance Oct 27 2016
Universal American ACOs and Fresenius Medical Care Partner to Improve Health of End Stage Renal... Oct 26 2016
Fresenius Kidney Care Tops Government’s National Five-Star Quality Ratings Oct 25 2016
Fresenius Medical Care Holdings, Inc. -- Moody's assigns Ba2 Issuer rating to FMC Holdings, outlook... Sep 29 2016
ETF’s with exposure to Fresenius Medical Care AG & Co. KGaA : September 12, 2016 Sep 12 2016
Fresenius SE & Co. KGaA -- Moody's affirms FSE's Baa3 issuer rating, outlook stable Sep 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)